Brought to you by 
Intrexon to acquire ERC specialist Medistem for $19.5mm in cash and stock
27 Aug 2020
Executive Summary
Intrexon Corp. (biological enabling platforms) acquired publicly traded regenerative medicine company Medistem Inc., which specializes in endometrial regenerative cells (ERCs), for $19.5mm in cash and stock (in the event of a share split, the deal value is not to exceed $26mm). For each of Medistem’s 14.4mm outstanding shares, stockholders received $0.27 in cash and $1.08 of an Intrexon share (approximately 0.54 of a share), equating to a 39% premium.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Intrexon to acquire ERC specialist Medistem for $19.5mm in cash and stock
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice